Impact of restrictive intravenous fluid replacement and combined epidural analgesia on perioperative volume balance and renal function within a Fast Track program.

BACKGROUND AND OBJECTIVE: Key factors of Fast Track (FT) programs are fluid restriction and epidural analgesia (EDA). We aimed to challenge the preconception that the combination of fluid restriction and EDA might induce hypotension and renal dysfunction. METHODS: A recent randomized trial (NCT00556790) showed reduced complications after colectomy in FT patients compared with standard care (SC). Patients with an effective EDA were compared with regard to hemodynamics and renal function. RESULTS: 61/76 FT patients and 59/75 patients in the SC group had an effective EDA. Both groups were comparable regarding demographics and surgery-related characteristics. FT patients received significantly less i.v. fluids intraoperatively (1900 mL [range 1100-4100] versus 2900 mL [1600-5900], P < 0.0001) and postoperatively (700 mL [400-1500] versus 2300 mL [1800-3800], P < 0.0001). Intraoperatively, 30 FT compared with 19 SC patients needed colloids or vasopressors, but this was statistically not significant (P = 0.066). Postoperative requirements were low in both groups (3 versus 5 patients; P = 0.487). Pre- and postoperative values for creatinine, hematocrit, sodium, and potassium were similar, and no patient developed renal dysfunction in either group. Only one of 82 patients having an EDA without a bladder catheter had urinary retention. Overall, FT patients had fewer postoperative complications (6 versus 20 patients; P = 0.002) and a shorter median hospital stay (5 [2-30] versus 9 d [6-30]; P< 0.0001) compared with the SC group. CONCLUSIONS: Fluid restriction and EDA in FT programs are not associated with clinically relevant hemodynamic instability or renal dysfunction.

L'articulation des rapports sociaux de sexe, de classe et de race dans la migration et le travail des femmes haïtiennes

Nombre de femmes paysannes haïtiennes migrent vers Port-au-Prince où elles deviennent travailleuses domestiques. Leur service domestique permet aux femmes qui les emploient de s'investir dans le travail non-domestique et de pouvoir accéder ainsi à la migration internationale. En France, ces migrantes deviennent à leur tour travailleuses domestiques, ce qui permet aux femmes françaises de s'investir dans le travail non-domestique. Ces phénomènes témoignent de l'existence d'une chaîne de travail et de migration où s'articulent les rapports sociaux de sexe, de classe, de race et les confrontations Nord/Sud, au coeur de la mondialisation néolibérale. Quelques-unes de ces femmes racontent leur histoire qui exprime à la fois la violence des rapports sociaux et leurs stratégies pour devenir sujet. Pour penser ces « Sujettes », je propose une approche qui croise la recherche féministe et la sociologie clinique sur les plans théorique, méthodologique et épistémologique. -- Many rural Haitian women migrate to Port-au-Prince and become domestic workers. Their domestic service allows other women to invest in the non-domestic work and access to international migration as well. In France, these Haitian migrants become domestic workers in turn, which allows French women to invest in the non-domestic work. These phenomena demonstrate the existence of a global work and migration chain where gender, class, race and the North/South confrontations are articulated, in the neoliberal globalization. Some of these women tell their life story which expresses both the violence of social problems and their strategies to become subject. To think these "subjects" I propose to cross feminist research and clinical sociology on the theoretical, methodological and epistemological point of view. Intersectionality among gender, race and class, North / South confrontations, productive and reproductive labour , domestic work, domestic service, care work , internal and international migration, neoliberal globalization, clinical sociology.

L'invention de la race : des représentations scientifiques aux exhibitions populaires

4e de couv.: Comment est né le concept moderne, scientifique, de "race" ? Pourquoi est-il devenu si rapidement hiérarchique, distinguant les "races inférieures" des "races supérieures" ? Et comment ce concept a-t-il pu revêtir une telle importance, aussi bien au sein de la communauté scientifique qu'auprès du grand public, au cours du XIXe siècle et du début du XXe siècle, jusqu'à être utilisé pour expliquer l'histoire et le devenir de l'humanité ? Autant d'interrogations, à l'origine de ce livre. L'invention de la race analyse la genèse des conceptions scientifiques de la "race", et montre que les nouvelles techniques de mesure et de représentation des corps racialisés opèrent une révolution visuelle majeure, inscrivant la différence humaine dans la biologie. Cet ouvrage avance qu'à partir d'une origine européenne, l'idée de race s'est étendue - par les connexions transnationales de réseaux scientifiques et marchands -, à tout l'Occident, mais aussi au Japon, à la Corée et à une partie de la Chine. Partout, elle suscite représentations et politique raciales discriminatoires. L'ouvrage montre aussi que les théories sur les hiérarchies raciales ont influencé les spectacles ethniques (dont les zoos humains), les expositions internationales et coloniales, la photographie ou les collections ethnographiques. Les expositions internationales et coloniales et l'internationalisation des spectacles ethniques ont largement véhiculé ces hiérarchies, contribuant forger une vision du monde fondée sur l'inégalité des races.

The forced adoption of a fast-track appraisal process for a breast cancer treatment in UK

Trastuzumab (Herceptin ®, Roche) is approved in UK for the treatment of the metastatic breast cancer since 2001. As of 2005, concomitantly with the publication of 3 studies that showed it produces a 50% reduction of the recurrence rates of breast cancer, trastuzumab started to be prescribed in the earlt adjuvant treatrnent of this disease. Und June 2006, trastuzumab did not have both: 1) regulatory approval and 2) NICE [National Institute for Health and Clinical Excellence] recommendation for the use in early stages of breast cancer. During the period until June 2006, the trastuzumab use in those patients was not reimbursed and because the cost of trastuzumab is equal with the yearly UK average income, most of patients could not self fund their treatrnent. Before the publication of the final NICE guidance, the new data of trastuzumab in early breast cancer raised enormous patient and professional interest and expectations. A great volume of public and professional pressure was generated to transcend a system by which Primary Care Trusts can reimburse a treatment only after a formal guidance was issued. This paper draw on a case study depicting and analyzing the process by which regulatory approval and NICE recommendations were achieved in a record time and how trastuzumab became a standard treatment on early adjuvant breast cancer. According to the data we gathered in this work we were witnessing one of the fastest processes of adoption of a health care technology since the creation of NICE, in 1999. This study addresses the following research question: How and why does the adoption pattern of trastuzumab differ from the rational decision-making model of the reimbursement process in UK? [Author, p. 4]